Lilly reaches insulin development deal with Adocia
Eli Lilly and Co. could pay more than $570 million to French pharmaceutical company Adocia under an agreement to develop a fast-acting insulin that is in the early stages of clinical testing.
Health Care
Articles
Nursing home construction moratorium fight fuels lobbying, donations
The two sides duking it out over a construction ban on nursing homes spent more than $475,000 over six months to win lawmakers to their sides—a spike of 37 percent over previous years. And that kind of high-stakes fight is about to happen again.
Pence: HIP 2.0 timeline not as important as approval
The state and federal government have been in negotiations since the summer, but the governor said he remains confident that an agreement will be reached, even if it isn’t by his original deadline.
Lilly bumps up dividend for first time since 2009
Shares of Eli Lilly and Co. were on the rise Tuesday morning, a day after the drugmaker announced its first dividend increase in more than five years.
Lilly’s Cyramza gets new marketing approval
Eli Lilly and Co.'s drug Cyramza has been approved as a treatment for lung cancer, regulators said. The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases that have spread.
Alzheimer’s tests present dilemma of knowing the future
While the tests will likely help drug companies like Eli Lilly and Co. evaluate medicines, they’ll also create wrenching personal and ethical dilemmas for patients who will have to live with the knowledge that they’re destined to develop the disease.
Indy dentist accused of $260,000 in false claims
Marion County Prosecutor Terry Curry said Dr. Bernice Avant was charged Thursday with one count of Medicaid fraud and four counts of theft.
Covance shareholder sues over $6.1B LabCorp deal
A Covance Inc. investor contends in a lawsuit that the drug-testing company’s board erred in relying on what the shareholder called Goldman Sachs Group Inc.’s conflict-tainted advice. Covance has major laboratory operations in Indianapolis.
Lilly rheumatoid arthritis drug meets goals in final-stage trial
If approved, Baricitinib may bring Lilly $673 million in 2020, according to the average of five analysts’ estimates compiled by Bloomberg.
Health law adding to primary care doctor shortage
A survey found that 81 percent of doctors say they are over-extended or at full capacity, and 44 percent plan to cut back on the number of patients they see, retire, work part-time or close their practice to new patients.
IU’s proton therapy center closes after 2,079 patients
John Kerstiens, the center's chief operating officer and chief financial officer, said the staff's mood on the final day of the center's operation was fraught with emotion.
Three hospitals part of plan to provide Ebola care
Indianapolis hospital leaders have spent the past two months ironing out a plan to deal with any cases of Ebola that emerge in Indiana. The plan is aimed at ensuring effective care while also minimizing the need to bring other hospital services to a virtual halt while patients are under care.
Feds drop case against former Lilly scientists accused of stealing secrets
Federal prosecutors dropped all charges against two scientists accused of stealing trade secrets worth $55 million from Eli Lilly and Co. after new information emerged last month, according to a court motion made Friday.
Growth rate for U.S. health tab may have hit bottom
U.S. health care spending grew by the slowest rate in more than a half-century last year, but a speed-up is expected as the economy finally gets traction.
Lilly competitor claims early success with Alzheimer’s drug
Biogen Idec Inc. shares rose Tuesday after the company said its Alzheimer’s drug showed promising early results and will be quickly moved into a final-stage trial.
WellPoint makes switch back to Anthem name
The nation's second-largest health insurance company has officially changed its corporate name from WellPoint Inc. to Anthem Inc. The Indianapolis-based insurer's stock starts trading Wednesday under the ticker symbol ANTM.
Lilly in $440M osteoporosis patch deal with Zosano
Eli Lilly and Co. said Tuesday it will team up with Zosano Pharma Corp. on an experimental osteoporosis patch in a deal that could be worth more than $440 million.
Lilly competitor Glaxo to shake up U.S. operations
A major drugmaker that was part of three-way multi-billion-dollar deal this year involving Eli Lilly and Co. is planning a reorganization that will include hundreds of job cuts in the United States.
Three insurers to split $151M in Medicaid contracts
Anthem Blue Cross and Blue Shield, MDwise Inc. and Managed Health Services were selected by the state officials to manage health care services for 84,000 Hoosiers that qualify as aged, blind or disabled.
Revenue has nearly tripled in past two years for blood-test maker
PTS Diagnostics engineered an about-face on its business plan five years ago, ditching its retail strategy to focus on serving physicians and nurse practitioners. This year, PTS is on pace to record revenue of nearly $50 million, up from $17 million two years ago.